Effects of phenylbutyrate on proliferation and apoptosis in human prostate cancer cells in vitro and in vivo

International Journal of Oncology

Volumn 14, Issue 3, 1999, Pages 501-508

  Melchior, Sebastian W ^a,c   Brown, Lisha G ^a   Figg, William D ^b   Quinn, Janna E ^a   Santucci, Richard A ^a   Brunner, Joachim ^c   Thüroff, Joachim W ^c   Lange, Paul H ^a   Vessella, Robert L ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Apoptosis; Cell cycle; Phenylbutyrate; Prostate cancer; Xenografts

Indexed keywords

ANDROGEN; ANTINEOPLASTIC AGENT; ARYLBUTYRIC ACID DERIVATIVE;

ANIMAL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL CULTURE; CELL CYCLE; CELL DIFFERENTIATION; CELL DIVISION; DISEASE MODEL; DRUG EFFECT; HUMAN; MALE; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; XENOGRAFT;

ANDROGENS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL DIFFERENTIATION; CELL DIVISION; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PHENYLBUTYRATES; PROSTATIC NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0033090991     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.14.3.501     Document Type: Article

References (29)

1. Samid D, Shack S and Sherman LT: Phenylacetate: a novel non-toxic inducer of tumor cell differentiation. Cancer Res 52: 1988-1992, 1992.
2. Brusilow SW, Danney M, Waber LJ, Batshaw M, Burton B, Levitsky L, Roth K, McKeethren C and Ward J: Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis. N Engl J Med 310: 1630-1634, 1984.
3. Watson AJ, Chambers T, Karp JE, Risch VR, Walker WG and Brusilow SW: Transient idiopathic hyperammonaemia in adults. Lancet II: 1271-1274, 1985.
4. Samid D, Shack S and Myers CE: Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by non-toxic pharmacological concentrations of phenylacetate. J Clin Invest 91: 2288-2295, 1993.
5. Adam L, Crepin M, Savin C and Israel L: Sodium phenylacetate induces growth inhibition and Bcl-2 down-regulation and apoptosis in MCF7ras cells in vitro and in nude mice. Cancer Res 56: 5156-5160, 1996.
6. Liu L, Shack S, Stetler Stevenson WG, Hudgins WR and Samid D: Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylbutyrate. J Invest Dermatol 103: 335-340, 1994.
7. Stockhammer G, Manley GT, Johnson R, Rosenblum MK, Samid D and Lieberman FS: Inhibition of proliferation and induction of differentiation in medulloblastoma- and astrocytoma-derived cell lines with phenylacetate. J Neurosurg 83: 672-681, 1995.
8. Pelidis MA, Carducci MA and Simons JW: Cytotoxic effects of sodium phenylbutyrate on human neuroblastoma cell lines. Int J Oncol 12: 889-893, 1998.
9. Piscitelli SC, Thibault A, Figg WD, Tompkins A, Headlee D, Lieberman R, Samid D and Myers CE: Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine. J Clin Pharmacol 35: 368-373, 1995.
10. Carducci MA, Nelson JB, Chan-Tack KM, Ayyagari SR, Sweatt WH, Campbell PA, Nelson WG and Simons JW: Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin Cancer Res 2: 379-387, 1996.
11. Bladou F, Vessella RL, Buhler KR, Ellis WJ, True LD and Lange PH: Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration. Int J Cancer 67: 785-790, 1996.
12. Ellis WJ, Vessella RL, Buhler KR, Bladou F, True LD, Bigler S, Curtis D and Lange PH: Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. Clin Cancer Res 2: 1039-1048, 1996.
13. Thibault A, Samid D, Cooper MR, Figg WD, Tompkins AC, Patronas N, Headlee DJ, Kohler DR, Venzon DJ and Myers CE: Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer 75: 2932-2938, 1995.
14. Berchem GJ, Bosseler M, Sugars LY, Voeller HJ, Zeitlin S and Gelmann EP: Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res 55: 735-738, 1995.
15. Gleave ME, Hsieh J, Wu H, von Eschenbach AC and Chung LWK: Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res 52: 1598-1605, 1992.
16. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, et al: WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169-1174, 1994.
17. Bissonette N and Hunting DJ: p21-induced cycle arrest in G1 protects cells from apoptosis induced by UV-irradiation or RNA polymerase II blockage. Oncogene 16: 3461-3469, 1998.
18. Archer SY, Meng S, Shei A and Hodin RA: p21 (WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA 95: 6791-6796, 1998.
19. Gorospe M, Shack S, Guyton KZ, Samid D and Holbrook NJ: Up-regulation and functional role of p21Waf1/Cip1 during growth arrest of human breast carcinoma MCF-7 cells by phenylacetate. Cell Growth Differ 7: 1609-1615, 1996.
20. Yamamoto H, Fujimoto J, Okamoto E, Furuyama J, Tamaoki T and Hashimoto-Tamaoki T: Suppression of growth of hepatocellular carcinoma by sodium butyrate in vitro and in vivo. Int J Cancer 76: 897-902, 1998.
21. Raffo AJ, Perlman H, Chen M, Day ML, Streitman JS and Buttyan R: Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55: 4438-4445, 1995.
22. Gleave ME, Sato N, Sadar M, Yago V, Bruchovsky N and Sullivan L: Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model. J Cell Biochem 69: 271-281, 1998.
23. Walls R, Thibault A, Liu L, Wood C, Kozlowski JM, Figg WD, Sampson ML, Elin RJ and Samid D: The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells. Prostate 29: 177-182, 1996.
24. Esquenet M, Swinnen JV, Heyns W and Verhoeven G: Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1 alpha, 25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate. Prostate 28: 182-194, 1996.
25. Adam L, Crepin M and Israel L: Tumor growth inhibition, apoptosis, and Bcl-2 down-regulation of MCF-7-ras tumors by sodium phenylacetate and tamoxifen combination. Cancer Res 57: 1023-1029, 1997.
26. Miller AC, Whittaker T, Thibault A and Samid D: Modulation of radiation response of human tumour cells by the differentiation inducers, phenylacetate and phenylbutyrate. Int J Radiat Biol 72: 211-218, 1997.
27. Ferrandina G, Melichar B, Loercher A, Verschraegen CF, Kudelka AP, Edwards CL, Scambia G, Kavanagh JJ, Abbruzzese JL and Freedman RS: Growth inhibitory effects of sodium phenylacetate (NSC 3039) on ovarian carcinoma cells in vitro. Cancer Res 57: 4309-4315, 1997.
28. Myers C, Cooper M, Stein C, Larocca R, Walther MM, Weiss G, Choyke P, Dawson N, Steinberg S, Uhrich MM, et al: Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 10: 881-889, 1992.
29. Eisenberger MA, Bezerdijan L and Kalash S: A critical assessment of the role of chemotherapy for endocrine-resistant prostatic carcinoma. Urol Clin North Am 14: 695-706, 1987.